Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Offers $120 Million For Corthera Eyeing Phase III Acute Cardiology Product

This article was originally published in The Pink Sheet Daily

Executive Summary

Relaxin enables the pharma to expand its reach in acute cardiology as its mega-drug Diovan faces patent expiries.

You may also be interested in...



Ranbaxy’s Ongoing Issues With FDA Continue Novartis Windfall With Diovan

Ranbaxy’s newest manufacturing site at Mohali, India, is prohibited by FDA from shipping products to the U.S., further delaying approval of generic valsartan. Novartis has recently revised its sales guidance due to lower than expected generic sales erosion in the U.S. this year.

Despite Challenges, Congestive Heart Failure Draws A Crowd

Biopharma companies are drawn to CHF, despite the lack of effective biomarkers and the need for large, expensive trials.

Despite Challenges, Congestive Heart Failure Draws A Crowd

Biopharma companies are drawn to CHF, despite the lack of effective biomarkers and the need for large, expensive trials.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel